Market Closed - Australian S.E. 02:10:19 2024-05-24 am EDT 5-day change 1st Jan Change
2.08 AUD +2.46% Intraday chart for PolyNovo Limited -5.45% +25.68%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
PolyNovo's Revenue Climbs 68.6% in April MT
Polynovo Gets India OK for Listing of Dermal Scaffold Device on Government e-Portal Marketplace MT
Transcript : PolyNovo Limited, H1 2024 Earnings Call, Feb 27, 2024
PolyNovo Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI
PolyNovo Secures Largest Single Order Worth AU$1.2 Million; Shares Rise 3% MT
PolyNovo Logs Record Monthly Sales in November MT
PolyNovo Limited Reports Unaudited Sales Results for the Month of November 2023 CI
Transcript : PolyNovo Limited - Shareholder/Analyst Call
Polynovo Secures Additional Funding from BARDA for Burn Treatment Trial MT
Transcript : PolyNovo Limited, 2023 Earnings Call, Aug 23, 2023
PolyNovo Limited Reports Earnings Results for the Full Year Ended June 30, 2023 CI
Immuron Appoints Paul Brennan as Board Chairman MT
PolyNovo Limited Reports Revenue Results for the Month and Nine Months Ended 31 March 2023 CI
PolyNovo Limited(ASX:PNV) added to S&P/ASX 200 Index CI
Polynovo Swings to Net Loss in Fiscal H1 on Employee, R&D Expansion; Shares Fall 4% MT
Transcript : PolyNovo Limited, H1 2023 Earnings Call, Feb 23, 2023
PolyNovo Limited Reports Earnings Results for the Half Year Ended December 31, 2022 CI
PolyNovo Limited Announces Update on SynPath Diabetic Foot Ulcer Trial CI
Transcript : PolyNovo Limited - Shareholder/Analyst Call
PolyNovo Limited Provides Unaudited Revenues Results for the First Half 2023 CI
Transcript : PolyNovo Limited Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-11-2023 07:30 AM
Polynovo to Raise AU$20 Million from Share Purchase Plan MT
Transcript : PolyNovo Limited - Pre Recorded Special Call
Polynovo Kicks Off $11 Million Share Offering MT
PolyNovo to Raise $20 Million in Institutional Placement; Shares Slip 9% MT
Chart PolyNovo Limited
More charts
PolyNovo Limited is an Australia-based medical device company, which is focused on advanced wound care that designs, develops, and manufactures dermal regeneration solutions using its patented NovoSorb biodegradable polymer technology. Its solutions include NovoSorb Biodegradable Temporizing Matrix (BTM) and NovoSorb MTX. NovoSorb BTM is a synthetic, biodegradable and biocompatible device designed to facilitate the dermis to grow within a patented polyurethane matrix when lost through extensive surgery, trauma or burn. NovoSorb BTM is indicated for use in the management of wounds, including partial and full thickness wounds, pressure ulcers, venous and diabetic ulcers, chronic and vascular ulcers, surgical wounds, trauma wounds and draining wounds. Its development program covers breast sling, hernia, and orthopedic applications. NovoSorb MTX is available in a range of sizes to address acute and chronic dermal wounds and is comprised of a 2mm biodegradable foam with no sealing membrane.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
2.08 AUD
Average target price
2.113 AUD
Spread / Average Target
+1.61%
Consensus
  1. Stock Market
  2. Equities
  3. PNV Stock
  4. News PolyNovo Limited
  5. Polynovo Secures Additional Funding from BARDA for Burn Treatment Trial